E1	Condition:T1 Name:T2
E3	Condition:T3 Severity:T40
E5	Condition:T5 Name:T6
E10	Eq-Comparison:T13 Operator:T11 Value:T12 Unit:T45 Per:T46
E12	Eq-Comparison:T16 Temporal-Period:T17
E2	Condition:T18 Name:T19
E4	Modifier:T20 Modifies:T19
E6	Observation:T21 Name:T22 Stage:E8
E8	Eq-Comparison:T23 Unit:T24 Value:T25 Value2:T26 Value3:T27
E11	Observation:T14 Name:T15 Temporality:E12
E13	Modifier:T28 Modifies:T15
E14	Condition:T29 Name:T30 Temporality:E15
E15	Eq-Comparison:T31 Temporal-Period:T32
E16	Eq-Comparison:T33 Temporal-Period:T34
E9	Modifier:T9 Modifies:E3
E18	Modifier:T10 Modifies:E3
E19	Modifier:T36 Modifies:E3
E20	Modifier:T37 Modifies:E3
E21	Modifier:T38 Modifies:E3
E23	Condition:T41 Name:T42
E24	Observation:T43 Name:T44 Numeric-Filter:E10
E25	Study:T47 
E27	Condition:T49 Name:T50 Polarity:T51
E28	Condition:T52 Name:T53
E7	Modifier:T7 Modifies:T53
E29	Modifier:T8 Modifies:T53
E31	Procedure:T55 Name:T56
E32	Contraindication:T57 Contraindicates:E31
E33	Condition:T58 Acuteness:T60 Acuteness:T59
E36	Study:T62 
E37	Risk:T63 Stability:T64
E38	Assertion:T65 Asserted:T64
E39	Drug:T66 Name:T67
E41	Study:T69 
E42	Other:T70 Is-Other:E41
E44	Negation:T72 Negates:T71
E45	Assertion:T73 Asserted:E44
T1	Condition 392 419	Neurodegenerative disorders
T2	Condition-Name 392 419	Neurodegenerative disorders
T3	Condition 373 380	disease
T5	Condition 447 464	Immunosuppression
T6	Condition-Name 447 464	Immunosuppression
T11	Eq-Operator 482 483	<
T12	Eq-Value 483 488	3,000
T13	Eq-Comparison 482 497	<3,000 cells/ml
T16	Eq-Comparison 211 216	Prior
T17	Eq-Temporal-Period 211 216	Prior
T18	Condition 135 138	SCI
T19	Condition-Name 135 138	SCI
T20	Modifier 109 134	non-penetrating traumatic
T21	Observation 144 165	Asia Impairment Scale
T22	Observation-Name 144 165	Asia Impairment Scale
T23	Eq-Comparison 166 185	grade of A, B, or C
T24	Eq-Unit 166 171	grade
T25	Eq-Value 175 176	A
T26	Eq-Value 178 179	B
T27	Eq-Value 184 185	C
T14	Observation 245 251	injury
T15	Observation-Name 245 251	injury
T28	Modifier 239 244	Brain
T29	Condition 280 289	infection
T30	Condition-Name 280 289	infection
T31	Eq-Comparison 272 279	ongoing
T32	Eq-Temporal-Period 272 279	ongoing
T33	Eq-Comparison 262 268	Recent
T34	Eq-Temporal-Period 262 268	Recent
T9	Modifier 363 372	endocrine
T10	Modifier 352 359	hepatic
T36	Modifier 345 350	renal
T37	Modifier 339 343	lung
T38	Modifier 323 337	cardiovascular
T40	Severity 311 322	significant
T41	Condition 430 436	Cancer
T42	Condition-Name 430 436	Cancer
T43	Observation 479 482	WBC
T44	Observation-Name 479 482	WBC
T45	Eq-Unit 489 494	cells
T46	Eq-Unit 495 497	ml
T47	Study 501 509	baseline
T49	Condition 531 534	HIV
T50	Condition-Name 531 534	HIV
T51	Polarity 534 535	+
T52	Condition 563 573	dependency
T53	Condition-Name 563 573	dependency
T7	Modifier 546 554	Chemical
T8	Modifier 558 562	ETOH
T55	Procedure 608 611	MRI
T56	Procedure-Name 608 611	MRI
T57	Contraindication 588 604	contraindication
T58	Condition 646 664	medical conditions
T59	Acuteness 638 645	chronic
T60	Acuteness 629 634	acute
T62	Study 746 751	study
T63	Risk 724 729	risks
T64	Stability 711 719	increase
T65	Assertion 707 710	may
T66	Drug 769 777	HB-adMSC
T67	Drug-Name 769 777	HB-adMSC
T69	Study 845 852	studies
T70	Other 815 820	other
T71	Encounter 886 902	follow-up visits
T72	Negation 858 871	Unwillingness
T73	Assertion 858 871	Unwillingness
A1	Eq-Operator-Value T11 LT
A3	Eq-Temporal-Period-Value T17 past
A2	Eq-Temporal-Period-Value T32 present
A4	Eq-Temporal-Period-Value T34 recent
A5	Severity-Value T40 severe
A6	Observation-Type-Value E24 lab
A8	Polarity-Value T51 positive
A10	Stability-Value T64 change
A11	Assertion-Type-Value E38 hypothetical
A12	Assertion-Type-Value E45 hypothetical
A13	Acuteness-Type-Value T60 acute
A14	Acuteness-Type-Value T59 chronic
R1	Equivalent-To Arg1:E24 Arg2:E5
R2	Caused-By Arg1:E36 Arg2:E37
R3	Caused-By Arg1:T64 Arg2:E33
R4	Or Arg1:E16 Arg2:E15
R5	Or Arg1:E18 Arg2:E9
R6	During Arg1:E24 Arg2:E25
R7	Or Arg1:E7 Arg2:E29
R8	Or Arg1:T60 Arg2:T59
R9	Or Arg1:E36 Arg2:E39
R10	Or Arg1:E19 Arg2:E18
R11	Or Arg1:E20 Arg2:E19
R12	Or Arg1:E21 Arg2:E20
